Alcobra Ltd fka ADHD

[midastouch017]

Alcobra's Metadoxine trial fails to show efficacy vs. placebo, share down AH • 5:30 PM
Douglas W. House, SA News Ed...
Lightly-traded nano cap Alcobra (ADHD +10.9%) slumps 13% AH on higher-than-average volume in response to a presentation of results from a Phase 2b clinical trial evaluating Metadoxine (vitamin B6 and L-PGA) for the treatment of attention deficit/hyperactivity disorder given by Dr. Lenard Adler at the American Academy of Child & Adolescent Psychiatry Meeting in San Diego.
On Slide 26, the graph shows that Metadoxine failed to demonstrate statistically significant efficacy compared to placebo at week six (p=0.136). This was the study's primary endpoint.